Review
Sep 2026
Drug survival of adalimumab across different manifestations of Behçet's syndrome: a retrospective analysis in 335 patients.
Evaluating the long-term drug survival of adalimumab in a large cohort of patients with Behçet's syndrome found a good retention rate at month 6, followed by a gradual decline in drug retention over time.
Ozge Sonmez, S. N. Esatoğlu, D. Uçar et al.
· Rheumatology · 0 citations